Hoitt Jason 4
4 · Stoke Therapeutics, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Stoke Therapeutics (STOK) CPO Jason Hoitt Sells Shares
What Happened
Jason Hoitt, Chief Patient Officer at Stoke Therapeutics (STOK), disposed of a total of 3,712 shares via open‑market sales on March 17–18, 2026, for aggregate proceeds of approximately $119,312. Individual reported transactions: 1,033 shares @ $32.74 ($33,820), 748 shares @ $33.38 ($24,965), 1,762 shares @ $31.28 ($55,122), 139 shares @ $31.79 ($4,419), and 30 shares @ $32.85 ($986). These sales are reported under sale code "S."
Key Details
- Dates: March 17, 2026 (two sales) and March 18, 2026 (three sales); Form 4 filed March 19, 2026 (timely).
- Transaction type: Sales (code S); footnote F1 indicates these were issuer‑mandated sales to satisfy tax withholding related to restricted stock unit (RSU) vesting/settlement.
- Price reporting: Reported prices are weighted averages; per footnotes the individual trades occurred across price ranges: $31.995–$32.99, $33.00–$33.855, $30.59–$31.58, and $31.60–$32.46. The filer can provide exact breakdowns on request.
- Shares owned after transaction: Not specified in the supplied excerpt of the filing—see the full Form 4 for post‑transaction holdings.
- Filing timeliness: Filed March 19, 2026 — appears timely relative to the transaction dates.
Context
These sales were routine, issuer‑mandated dispositions to cover tax withholding on RSU vesting (per F1), which is a common administrative action and not itself a directional signal about insider sentiment. The weighted‑average pricing and price ranges reflect multiple smaller trades executed on the listed dates. For complete holdings and exact per‑trade breakdowns, consult the full Form 4 filing (Accession No. 0001762572-26-000006).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-17$32.74/sh−1,033$33,820→ 12,955 total - Sale
Common Stock
[F1][F3]2026-03-17$33.38/sh−748$24,965→ 12,207 total - Sale
Common Stock
[F1][F4]2026-03-18$31.28/sh−1,762$55,122→ 10,445 total - Sale
Common Stock
[F1][F5]2026-03-18$31.79/sh−139$4,419→ 10,306 total - Sale
Common Stock
[F1]2026-03-18$32.85/sh−30$986→ 10,276 total
Footnotes (5)
- [F1]The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.